4.1 Article

Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation

Journal

JOURNAL OF MEDICAL ECONOMICS
Volume 15, Issue 4, Pages 635-643

Publisher

Informa Healthcare
DOI: 10.3111/13696998.2012.667028

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available